Nateglinide

Nateglinide

Systematic (IUPAC) name
3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Clinical data
Trade names	Starlix
AHFS/Drugs.com	monograph
MedlinePlus	a699057
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	?
Legal status	POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Protein binding	98%
Half-life	1.5 hours
Identifiers
CAS number	105816-04-4 Y
ATC code	A10BX03
PubChem	CID 60026
DrugBank	APRD00593
ChemSpider	10482084 Y
UNII	41X3PWK4O2 Y
KEGG	D01111 N
ChEMBL	CHEMBL286559 N
Chemical data
Formula	C19H27NO3
Mol. mass	317.423 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 Y Key:OELFLUMRDSZNSF-BRWVUGGUSA-N Y
N(what is this?)  (verify)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

External links

• Starlix - website of the manufacturer.
• How Nateglinide Works - website of the manufacturer.